Lower riskDrug recall · FDA · Published February 12, 2020
Lupin Memantine Capsules Recall: Failed Dissolution Test Risk
Lupin Pharmaceuticals recalls 21mg Memantine Hydrochloride Extended Release Capsules due to failed dissolution tests. This may affect drug effectiveness. Check NDC 68180-248-06 and lot H900330 for affected products.
Failed Dissolution Specifications: Low out of specification results observed in dissolution test at six-month long-term stability study.
Take action
Contact the company
📍Recalling firmLupin Pharmaceuticals Inc.Harborplace Tower, 111 S Calvert St Fl 21st · Baltimore, MD 21202-6174
✎ GovInfoNow plain-language explainer
Lupin Pharmaceuticals is recalling 21 mg Memantine Hydrochloride Extended Release Capsules (30-count bottles) because they failed dissolution tests during stability studies. This could mean the medication doesn't work as intended, but the recall doesn: t mention immediate safety risks. Read more at govinfonow.com/recall/37374-lupin-memantine-capsules-recall-failed-dissolution-test-risk.
“Lupin Memantine Capsules Recall: Failed Dissolution Test Risk.” GovInfoNow, updated October 5, 2026. https://govinfonow.com/recall/37374-lupin-memantine-capsules-recall-failed-dissolution-test-risk. Based on FDA recall #D-0855-2020 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0855-2020%22&limit=1).
Lupin Pharmaceuticals Inc. recalled Memantine Hydrochloride Extended Release Capsules, 21 mg, 30-count bottles, on Feb. 12, 2020, according to the FDA. The recall addresses failed dissolution specifications observed in stability testing.
The product failed dissolution specifications because low out-of-specification results were observed in a dissolution test during a six-month long-term stability study.
Context
GovInfoNow's records show Lupin Pharmaceuticals Inc. has had 90 other recalls on record since Jan. 31, 2013. Other recent recalls of similar products include Lupin Clobetasol Cream Recall (Aug. 3, 2026), Lupin Glucagon Emergency Kit Recall (June 23, 2026), and Lupin prednisolone acetate ophthalmic suspension recall (June 4, 2026). Other recent recalls of similar products include Harvard Drug Group Memantine Capsules Recall (March 24, 2026), Sun Pharmaceutical Lisdexamfetamine Capsules Recall (Oct. 28, 2025), and Ascend Minocycline Tablets Recall (June 1, 2026).
How to tell if you have this one
Check for the NDC code 68180-248-06 on the product label and lot number H900330. These capsules are prescription-only and manufactured by Lupin Pharmaceuticals.
Brand
Lupin
Category
Drug
Based on the official FDA remedy
What to do — step by step
Check Product Label
Look for NDC 68180-248-06 and lot number H900330 on the bottle.
Where it went and when
Where it was distributed
Distributed nationwide.
Nationwide
Not listed
FDA distribution: “Nationwide within the United States.” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 16 months after the firm started it.
1Firm started the recall
2Published in FDA’s Enforcement Report
3FDA classified it Class II
4FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
Official source: FDA Recall #D-0855-2020 (February 12, 2020) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0855-2020 to see it in context.
Plain-language summary written by qwen3:4b on October 5, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.